MedWatch

Union Therapeutics on new Covid-19 deal: Treatments can be easier and cheaper

A new options agreement with US company TFF Pharmaceuticals gives Union Therapeutics access to a potentially cheaper version of the drug Niclosamide, which the firm is already developing as treatment against Covid-19.

Foto: Union Therapeutics

Union Therapeutics has not been involved in the development of Covid-19 treatments for many months, but nonetheless, the company is pacing forward at full speed and currently taking one of its drugs through phase I.

Now the company has taken another step down the Covid-19 path with a major options agreement with Texan company TFF Pharmaceuticals, which may ultimately cost Union Therapeutics up to USD 210m.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier